OTC Artificial Tears Market Analysis: A Growing Focus on Eye Health

Global OTC Artificial Tears Market Projected to Reach $6.25 Billion by 2030

According to Renub Research, the global OTC artificial tears market is set to achieve a valuation of $6.25 billion by 2030, expanding at a CAGR of 4.87% (2024–2030). The rising prevalence of dry eye syndrome (DES) and increased awareness of eye health are major factors propelling market growth. Over-the-counter artificial tears offer a convenient solution to combat discomfort, dryness, and inflammation, making them an indispensable component of modern eye care.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=otc-artificial-tears-market-p.php

Key Drivers Fueling Market Growth

1. Growing Prevalence of Dry Eye Syndrome (DES)

• Estimates from BMC Ophthalmology indicate that 9.5% to 90% of populations worldwide are affected by dry eye syndrome, varying by region.
• Despite not being life-threatening, DES significantly impacts quality of life, highlighting the importance of accessible and effective treatments like artificial tears.

2. Aging Population and Increased Eye Surgeries

• Age-related ocular conditions and post-surgical care have escalated the demand for artificial tears.
• Older adults are more susceptible to eye-related issues such as macular degeneration and diabetic retinopathy, amplifying market growth.

3. Extended Screen Time and Digital Eye Strain

• Children and adults spend an average of 7.5 hours daily on screens (CDC, 2023).
• Increased exposure to blue light and digital devices exacerbates eye dryness, driving demand for solutions like OTC artificial tears.

4. Product Innovation and Technological Advancements

• Preservative-free and multi-dose artificial tears, such as SYSTANE HYDRATION PF and REFRESH RELIEVA, cater to diverse consumer needs.
• Companies are investing in research to develop tailored solutions, improving user convenience and efficacy.

Regional Highlights

Europe: A Market Leader in Eye Care

• Europe’s aging population and rising rates of age-related macular degeneration (AMD) contribute to its dominance.
• According to EURETINA, 34 million EU residents experience AMD annually, with this figure expected to rise by 25% by 2050.

United States: A Thriving Market

• In the U.S., 16 to 49 million people, primarily women, suffer from dry eye syndrome.
• The presence of advanced healthcare infrastructure, high disposable incomes, and proactive consumer awareness drives market expansion.

Product Segmentation: Solutions at the Forefront

The global OTC artificial tears market is segmented by product type:

1. Solution – The most widely used, offering rapid relief and ease of application.
2. Ointment
3. Emulsion
4. Gel
5. Spray Solution
6. Suspensions

Solutions dominate due to their user-friendly liquid formulation and broad applicability, especially for sensitive eyes or contact lens wearers.

Applications: Dry Eye Syndrome Leads

1. Dry Eye Syndrome – A primary driver due to increasing diagnosis rates and lifestyle changes.
2. Allergies
3. Infections
4. UV and Blue Light Protection
5. Contact Lens Moisture Retention
6. Others

The growing incidence of dry eye syndrome underscores the sustained demand for convenient and effective remedies.

Distribution Channels: Accessibility Drives Growth

The market is divided into the following channels:

1. Drugstores & Supermarkets – Offering convenience and variety, these outlets lead the market.
2. Online Pharmacies – Rapidly growing due to the ease of ordering and home delivery.
3. Retail Pharmacies
4. Others

Drugstores remain a consumer favorite for their trusted reputation and immediate availability of products.

Competitive Landscape

Major players driving the global OTC artificial tears market include:

• AbbVie Inc.
• Akorn Inc.
• Alcon
• Bausch Health Companies Inc.
• Johnson & Johnson
• Nicox S.A.
• Novartis AG
• Santen Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Ltd.

Recent Developments

In December 2023, Johnson & Johnson Vision Care launched a Phase II clinical trial for preservative-free lubricating eye drops using Novelia® Eye Droppers for non-contact lens users.

Related Reports

United States Contact Lenses Market

Saudi Arabia Contact Lenses Market

Intraocular Lens Market

About Renub Research

Renub Research is a premier Market Research and Advisory company with over 15 years of experience. We specialize in:

• Global Market Research
• Business Surveys
• Management Consulting

Industries We Serve

Our expertise spans Healthcare, Food & Beverages, IT, Consumer Goods, and more.

Our Services

We provide detailed insights to aid strategic decision-making, offering solutions tailored to address market challenges.

For comprehensive market analysis, visit Renub Research or request a free sample report: Click Here.